- Trials with a EudraCT protocol (625)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
625 result(s) found for: Hard tissue.
Displaying page 1 of 32.
EudraCT Number: 2005-001614-41 | Sponsor Protocol Number: CSTI571BIT06 | Start Date*: 2005-05-19 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: OPEN-LABEL TRIAL OF GLIVEC IMATINIB MESYLATE IN PATIENTS WITH REFRACTORY DESMOPLASTIC SMALL ROUND CELL TUMORS DSRCT EXPRESSING A MOLECULAR TARGET OF GLIVEC PDGF-R AND/OR C-KIT | |||||||||||||
Medical condition: TREATMENT OF PATIENTS WITH REFRACTORY DESMOPLASTIC SMALL ROUND CELL TUMORS DSRCT . | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001478-10 | Sponsor Protocol Number: Z3 | Start Date*: 2009-02-01 | |||||||||||
Sponsor Name:Universitätsklinikum Tübingen | |||||||||||||
Full Title: CWS-2007-HR: A randomised phase-III trial of the Cooperative Weichteilsarkom Studiengruppe for localised high-risk Rhabdomyosarcoma and localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in childr... | |||||||||||||
Medical condition: localized High Risk Soft Tissue Sarcoma in patients younger than 21 years | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) SE (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011280-37 | Sponsor Protocol Number: ET2008-102 | Start Date*: 2009-11-05 | |||||||||||
Sponsor Name:Centre Léon Bérard | |||||||||||||
Full Title: Efficacy and safety assessment of oral LBH589 in adult patients with advanced soft tissue sarcoma after doxorubicin failure: an open-label, multi-centric phase II study | |||||||||||||
Medical condition: Patients adultes atteints de sarcome des tissus mous au stade avancé ou métastatique, présentant une progression sous ou après traitement à base de Doxorubicine | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012644-16 | Sponsor Protocol Number: 361/09 | Start Date*: 2009-07-24 | ||||||||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | ||||||||||||||||||
Full Title: PHASE 2 SINGLE- ARM STUDIES OF TEMOZOLOMIDE IN COMBINATION WITH TOPOTECAN IN REFRACTORY AND RELAPSED NEUROBLASTOMA AND OTHER PAEDIATRIC SOLID TUMOURS | ||||||||||||||||||
Medical condition: NEUROBLASTOMA AND OTHER PAEDIATRIC SOLID TUMOURS | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002512-27 | Sponsor Protocol Number: NL44774.068.13 | Start Date*: 2013-11-25 |
Sponsor Name:Maastricht University | ||
Full Title: The role of bile acids in human brown adipose tissue metabolism | ||
Medical condition: Healthy subjects | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001466-25 | Sponsor Protocol Number: MW2013-07-10 | Start Date*: 2015-06-18 |
Sponsor Name:MediWound, Ltd. | ||
Full Title: A multicenter, prospective, randomized, vehicle controlled, assessor blinded study performed in subjects with hard to heal wounds, to evaluate the efficacy and safety of enzymatic debridement with ... | ||
Medical condition: Hard to heal venous leg ulcers, diabetic lower extremity ulcers and traumatic/post operative wounds. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-007125-39 | Sponsor Protocol Number: LeBenD | Start Date*: 2011-04-19 |
Sponsor Name:Klinik f. Innere Med., Fachabteilung Hämatologie | ||
Full Title: A phase I-II trial of lenalidomide, bendamustin and dexamethasone in the treatment of patients with systemic AL-amyloidosis and ineligible for stem cell transplantation | ||
Medical condition: AL-amyloidose | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-001951-39 | Sponsor Protocol Number: ST1481-DM-04-004 | Start Date*: 2005-12-14 | |||||||||||
Sponsor Name:SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | |||||||||||||
Full Title: "Estudio fase II de Gimatecan (ST1481) como tratamiento de rescate en pacientes con sarcoma de partes blandas avanzado o metastático y recidivados después de un régimen de quimioterapia basado en a... | |||||||||||||
Medical condition: sarcoma de partes blandas avanzado o metastático | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005091-41 | Sponsor Protocol Number: CTU A005 | Start Date*: 2007-03-16 |
Sponsor Name:RIEMSER Arzneimittel AG | ||
Full Title: A prospective, randomized, observer-blind, reference-controlled (Provicol ®) Phase III clinical study on the efficacy and safety of Ledermix® Zementpulver after the treatment (preparation) of teeth... | ||
Medical condition: Teeth with dentine carious lesions without clinical symptoms of inflammation, and / or Teeth with defective filling margins | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002312-41 | Sponsor Protocol Number: MK-3475-365 | Start Date*: 2016-10-22 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | |||||||||||||
Full Title: Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) | |||||||||||||
Medical condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: ES (Temporarily Halted) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) NL (Ongoing) AT (Trial now transitioned) FI (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004109-15 | Sponsor Protocol Number: 1ABC | Start Date*: 2017-12-13 | |||||||||||
Sponsor Name:Medical University of Warsaw | |||||||||||||
Full Title: Evaluation of the safety and efficacy of the treatment of chronic wounds in diabetic foot syndrome with the use of autologous stem cells isolated from adipose tissue - within the project: "Therapeu... | |||||||||||||
Medical condition: Diabetic foot ulcer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005818-10 | Sponsor Protocol Number: AGMT_MALT-2 | Start Date*: 2012-05-02 | |||||||||||
Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH | |||||||||||||
Full Title: PHASE II TRIAL OF RITUXIMAB (MABTHERA®) PLUS LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT) | |||||||||||||
Medical condition: Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004937-19 | Sponsor Protocol Number: CMHV370A12201 | Start Date*: 2021-09-08 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: A multi-center, randomized, participant- and investigator- blinded, placebo-controlled, parallel group basket study to evaluate the safety, tolerability and efficacy of MHV370 in participants with ... | ||||||||||||||||||
Medical condition: Sjögren’s syndrome Mixed connective tissue disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) HU (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-011097-15 | Sponsor Protocol Number: OLA_ZIPRA | Start Date*: 2009-08-25 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie | ||
Full Title: Effect of atypical antipsychotics on gene expression in soft tissues of healthy subjects. A placebo controlled randomised pilot study. | ||
Medical condition: The study will be conducted in 42 healthy volunteers | ||
Disease: | ||
Population Age: | Gender: Male | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001194-16 | Sponsor Protocol Number: DDD17CRCP2 | Start Date*: 2017-12-11 |
Sponsor Name:KU Leuven | ||
Full Title: Pharmacokinetics of celecoxib for the prevention/treatment of colorectal cancer: optimization of intestinal sampling for celecoxib in healthy volunteers | ||
Medical condition: Colorectal cancer | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-002029-40 | Sponsor Protocol Number: 1001 | Start Date*: 2013-08-23 |
Sponsor Name:Karolinska Institutet | ||
Full Title: Aprepitant – effect and safety in treatment of atopic dermatitis | ||
Medical condition: Atopic Dermatitis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000536-10 | Sponsor Protocol Number: LL-37002 | Start Date*: 2018-08-13 | |||||||||||
Sponsor Name:Promore Pharma AB | |||||||||||||
Full Title: A Study in Patients with Hard-to-Heal Venous Leg Ulcers to Measure Efficacy and Safety of Locally Administered LL-37; A Phase IIb, Double-blind, Randomised, Placebo-controlled, Multi-centre Trial | |||||||||||||
Medical condition: Hard-to-Heal (HTH) venous leg ulcer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001245-14 | Sponsor Protocol Number: CC-5013-NHL-007 | Start Date*: 2013-12-13 | ||||||||||||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||||||||||||
Full Title: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lym... | ||||||||||||||||||||||||||||
Medical condition: Relapsed/refractory indolent lymphoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) CZ (Completed) IT (Completed) PT (Completed) ES (Completed) PL (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-003295-31 | Sponsor Protocol Number: C3441021 | Start Date*: 2019-03-15 | ||||||||||||||||
Sponsor Name:Pfizer Inc. | ||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of Talazoparib With Enzalutamide In Metastatic Castration-resistant Prostate Cancer | ||||||||||||||||||
Medical condition: Metastatic Castration-resistant Prostate Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: SE (Trial now transitioned) DE (Trial now transitioned) NO (Trial now transitioned) GB (GB - no longer in EU/EEA) CZ (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002100-41 | Sponsor Protocol Number: LL-37001B | Start Date*: 2012-07-12 | |||||||||||
Sponsor Name:Lipopeptide AB | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled, safety and pilot dose-response study of LL-37 in hard-to-heal venous leg ulcers | |||||||||||||
Medical condition: Hard-to-heal (HTH) venous leg ulcer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
